Strong balance sheet maintained while advancing three clinical programs. Conference call to be held today at 8:00 AM ET to discuss operational highlights and future outlook.
Nexalife Pharmaceuticals today reported financial results for the second quarter ended June 30, 2023.
- Cash Position: Cash, cash equivalents, and marketable securities were $450 million.
- R&D Expenses: Research and development expenses were $45 million.
- G&A Expenses: General and administrative expenses were $15 million.